RNA polymerase II inhibitor - Hamlet Pharma AB
Alternative Names: NlpD immunotherapy programme; RNA pol II inhibitor - Hamlet Pharma AB; RNA pol II inhibitor immunotherapyLatest Information Update: 17 Jan 2024
At a glance
- Originator SelectImmune Pharma
- Class Anti-inflammatories; Biological proteins; Immunotherapies
- Mechanism of Action RNA polymerase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Inflammation